RxDoctor Payments Data

Lauren Herron

Adult Health · Evansville, INNPI 1205320637

Payments from drug & device makers

$2,588in general payments, 2019–2025

Across 154 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$973
  • Regeneron Healthcare Solutions, Inc.$317
  • Galderma Laboratories, L.p.$295
  • Sanofi$175
  • Dermavant Sciences, Inc.$171
  • Incyte Corporation$103
  • plus $554 from 13 others

What the payments were for

  • Food & beverage$2,27588%
  • Education$31312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,588 in reported general payments places this provider in the 80th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$128,185
Medicare patients
641
Services billed
3,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab18$195,544
TremfyaGuselkumab11$152,781
Dupixent SyringeDupilumab13$57,277
Clobetasol Propionate134$5,424
Ketoconazole200$2,884
Fluorouracil31$2,808
Clindamycin Phosphate59$2,061
Mycophenolate Mofetil13$1,321
Tacrolimus12$1,319
Triamcinolone Acetonide57$1,175
Hydroxychloroquine Sulfate18$1,139
Doxycycline Monohydrate41$937
Hydrocortisone54$677
Acitretin11$294
Doxycycline Hyclate15$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$973$152,78111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 adult health providers in Indiana.

Other adult health in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →